Clinical trials: Obese Subjects
Obesity
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
To evaluate the effect of 6-month administration of CP-945,598 on: weight loss and waist circumference, blood pressure, cholesterol, glucose other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α…
- Trial name
- NCT00134199
- Testing
- CP-945,598, sibutramine
- Where
- 15 sites in United States
- Volunteers
- 282 people
- Sponsor
- Pfizer
Overweight or Obese
Phase II Study of THDBH120 Injection in Overweight or Obese Subjects
To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.
- Trial name
- NCT07036601
- Testing
- THDBH120 injection
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Weight Loss, Obesity
Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition
This is a Phase 2 randomized, double-blind, placebo-controlled, parallel arm study of NA-931 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.
- Conditions
- Weight Loss, Obesity, Body Weight, Body Weight Changes
- Trial name
- NCT06564753
- Testing
- NA-931, dose 1, daily and orally, NA-931, dose2, daily and orally, NA-931 dose 3, daily and orally
- Where
- 5 sites in Australia
- Volunteers
- 126 people
- Sponsor
- Biomed Industries, Inc.
Chronic Weight Management
Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects
The Objective of this trial is to evaluate the long-term safety, tolerability, weight loss efficacy and metabolic benefits of HRS-7535 tablets inobesity.
- Trial name
- NCT06671821
- Testing
- HRS-7535
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity
Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.
- Trial name
- NCT00709371
- Testing
- Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day
- Where
- 20 sites in United States
- Volunteers
- 729 people
- Sponsor
- Orexigen Therapeutics, Inc
Atherosclerosis
A Study on Intima Media Thickness (IMT) in Middle-aged Subjects
This is an observational study to measure the thickness of artery walls in the neck (intima media thickness IMT) by ultrasound examination in middle-aged subjects with central obesity.
- Trial name
- IMT (NCT00784264)
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
A Phase 2 study Comparing the effects on glucose control of MEDI0382 in combination with Dapagliflozin and Metformin compared to placebo in combination with Dapagliflozin and Metformin in overweight/obese participants with Type 2…
- Trial name
- NCT03444584
- Testing
- MEDI0382, Dapaglifozin, Metformin
- Where
- 8 sites in Germany, Hungary and 1 more
- Volunteers
- 49 people
- Sponsor
- MedImmune LLC
Metabolic Syndrome, Overweight
Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome
The objective of this study was to investigate from 3 sites (University of Connecticut, University of Florida, and University of California, Irvine) whether enhancement of a modified Mediterranean-style, low glycemic load diet…
- Conditions
- Metabolic Syndrome, Overweight, Obesity, Hypercholesterolemia
- Trial name
- HMS4 (NCT01010841)
- Testing
- UltraMealPlus 360 (Medical food), Low-glycemic-load diet
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- MetaProteomics LLC
Healthy Volunteers
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects.
- Trial name
- NCT02475317
- Testing
- Maralixibat, Volixibat
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Mirum Pharmaceuticals, Inc.
Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.
- Trial name
- NCT06994650
- Testing
- HRS9531
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity
A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients
The purpose of this study is to determine if CP-945,598 is effective in the prevention of weight regain in obese subjects.
- Trial name
- NCT00483171
- Testing
- CP-945,598, Non-pharmacological weight loss program (NPP), Low Calorie Diet
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 699 people
- Sponsor
- Pfizer
Overweight, Obesity
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- STEP7 (NCT04251156)
- Testing
- Semaglutide
- Where
- 33 sites in Brazil, China and 2 more
- Volunteers
- 375 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 2 (NCT03552757)
- Testing
- Semaglutide 1.0 mg, Semaglutide 2.4 mg
- Where
- 147 sites in United States, Argentina and 11 more
- Volunteers
- 1,210 people
- Sponsor
- Novo Nordisk A/S
Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF)
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in Chinese subjects with heart failure with ejection fraction retention/mild ejection fraction…
- Conditions
- Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction
- Trial name
- NCT06862908
- Testing
- IBI362
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
The purpose of the study is to determine the safety and weight loss when sibutramine is used in overweight and obese subjects.
- Trial name
- NCT00234988
- Testing
- sibutramine hydochloride monohydrate
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Abbott
Diabetes, Metabolism and Nutrition Disorder
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
This trial is conducted in Europe. The aim of the trial is to investigate the effect of semaglutide on energy intake, appetite sensations, postprandial glucose and triglyceride metabolism and gastric emptying in obese subjects…
- Conditions
- Diabetes, Metabolism and Nutrition Disorder, Obesity
- Trial name
- NCT02079870
- Testing
- semaglutide
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
Phase Ib Clinical Study of HDM1005 Injection
This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation study in overweight or obese subjects to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD)…
- Trial name
- NCT06637020
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Overweight, Obesity
Safety and Efficacy of Litramine in Overweight and Obese Subjects
Preparations that bind to nutritional fat and inhibit its absorption could be decisively meaningful for the regulation of bodyweight or obesity.
- Conditions
- Overweight, Obesity, Weight Loss
- Trial name
- NCT01233349
- Testing
- Litramine
- Where
- Germany
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Healthy
Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers
The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of increasing doses of canagliflozin (JNJ-28431754) in healthy obese…
- Trial name
- NCT01756404
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2
Effects of the GOLO for Life System Diet With and Without GOLO Release Supplement on Glycemic Control and Insulin Resistance
This randomized, double-blind placebo-controlled study is intended to observe the short-term effects of the GFL System Diet with Release supplement versus GFL System Diet with placebo on glycemic metabolism and insulin resistance…
- Trial name
- NCT04082390
- Testing
- RELEASE
- Volunteers
- 36 people
- Sponsor
- Golo